[CITATION][C] Targeted therapy trials: approval strategies, target validation, or helping patients?
Journal of Clinical Oncology: Official Journal of the American Society …, 2007•europepmc.org
A comment on this article appears in" Targeted therapies: cui prodest?" J Clin Oncol. 2007
Oct 10; 25 (29): 4691-2; author reply 4692. This is a comment on" Open-label phase III trial
of panitumumab plus best supportive care compared with best supportive care alone in
patients with chemotherapy-refractory metastatic colorectal cancer." J Clin Oncol. 2007 May
1; 25 (13): 1658-64.
Oct 10; 25 (29): 4691-2; author reply 4692. This is a comment on" Open-label phase III trial
of panitumumab plus best supportive care compared with best supportive care alone in
patients with chemotherapy-refractory metastatic colorectal cancer." J Clin Oncol. 2007 May
1; 25 (13): 1658-64.
A comment on this article appears in" Targeted therapies: cui prodest?" J Clin Oncol. 2007 Oct 10; 25 (29): 4691-2; author reply 4692. This is a comment on" Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer." J Clin Oncol. 2007 May 1; 25 (13): 1658-64.
europepmc.org